VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting
VBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual Meeting
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
VBI Vaccines Inc.（納斯達克股票代碼：VBIV）（VBI）是一家以免疫學爲動力、追求強有力的疾病預防和治療的生物製藥公司。該公司正在進行的複發性膠質母細胞瘤（GBM）癌症疫苗免疫治療候選藥物 VBI-1901 的隨機、對照的2b期研究的新中期腫瘤反應數據已獲2024年美國學會海報發佈臨床腫瘤學（ASCO）年會。
The presentation at ASCO will provide an update to the encouraging data previously shared at the World Vaccine Congress Washington in April, including additional data from those initially evaluable patients, as well as data from new patients who have since been randomized into the Phase 2b study.
ASCO的演講將提供先前在4月華盛頓世界疫苗大會上分享的令人鼓舞的數據的最新情況，包括來自最初可評估患者的更多數據，以及此後被隨機分配到2b期研究的新患者的數據。
譯文內容由第三人軟體翻譯。